Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside
Mucositis is one of the most common debilitating side effects related to chemotherapy (CT), radiation therapy (RT), targeted agents and immunotherapy. It is a complex process potentially involving any portion of the gastrointestinal tract and injuring the mucosa, leading to inflammatory or ulcerativ...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/6/857 |
| _version_ | 1797711458023243776 |
|---|---|
| author | Debora Basile Paola Di Nardo Carla Corvaja Silvio Ken Garattini Giacomo Pelizzari Camilla Lisanti Lucia Bortot Lucia Da Ros Michele Bartoletti Matteo Borghi Lorenzo Gerratana Davide Lombardi Fabio Puglisi |
| author_facet | Debora Basile Paola Di Nardo Carla Corvaja Silvio Ken Garattini Giacomo Pelizzari Camilla Lisanti Lucia Bortot Lucia Da Ros Michele Bartoletti Matteo Borghi Lorenzo Gerratana Davide Lombardi Fabio Puglisi |
| author_sort | Debora Basile |
| collection | DOAJ |
| description | Mucositis is one of the most common debilitating side effects related to chemotherapy (CT), radiation therapy (RT), targeted agents and immunotherapy. It is a complex process potentially involving any portion of the gastrointestinal tract and injuring the mucosa, leading to inflammatory or ulcerative lesions. Mechanisms and clinical presentation can differ according both to the anatomic site involved (oral or gastrointestinal) and the treatment received. Understanding the pathophysiology and management of mucosal injury as a secondary effect of anti-cancer treatment is an important area of clinical research. Prophylaxis, early diagnosis, and adequate management of complications are essential to increase therapeutic success and, thus, improve the survival outcomes of cancer patients. This review focuses on the pathobiology and management guidelines for mucositis, a secondary effect of old and new anti-cancer treatments, highlighting recent advances in prevention and discussing future research options. |
| first_indexed | 2024-03-12T07:07:23Z |
| format | Article |
| id | doaj.art-a3e32558a2b641beba8d9241e4b1eb63 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T07:07:23Z |
| publishDate | 2019-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a3e32558a2b641beba8d9241e4b1eb632023-09-02T23:20:36ZengMDPI AGCancers2072-66942019-06-0111685710.3390/cancers11060857cancers11060857Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to BedsideDebora Basile0Paola Di Nardo1Carla Corvaja2Silvio Ken Garattini3Giacomo Pelizzari4Camilla Lisanti5Lucia Bortot6Lucia Da Ros7Michele Bartoletti8Matteo Borghi9Lorenzo Gerratana10Davide Lombardi11Fabio Puglisi12Department of Medicine (DAME), University of Udine, 33100 Udine, ItalyDepartment of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyDepartment of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyIntensive Care Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyDepartment of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyMucositis is one of the most common debilitating side effects related to chemotherapy (CT), radiation therapy (RT), targeted agents and immunotherapy. It is a complex process potentially involving any portion of the gastrointestinal tract and injuring the mucosa, leading to inflammatory or ulcerative lesions. Mechanisms and clinical presentation can differ according both to the anatomic site involved (oral or gastrointestinal) and the treatment received. Understanding the pathophysiology and management of mucosal injury as a secondary effect of anti-cancer treatment is an important area of clinical research. Prophylaxis, early diagnosis, and adequate management of complications are essential to increase therapeutic success and, thus, improve the survival outcomes of cancer patients. This review focuses on the pathobiology and management guidelines for mucositis, a secondary effect of old and new anti-cancer treatments, highlighting recent advances in prevention and discussing future research options.https://www.mdpi.com/2072-6694/11/6/857mucosal injurymucositismucosal impairmentanti-cancer treatments |
| spellingShingle | Debora Basile Paola Di Nardo Carla Corvaja Silvio Ken Garattini Giacomo Pelizzari Camilla Lisanti Lucia Bortot Lucia Da Ros Michele Bartoletti Matteo Borghi Lorenzo Gerratana Davide Lombardi Fabio Puglisi Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside Cancers mucosal injury mucositis mucosal impairment anti-cancer treatments |
| title | Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside |
| title_full | Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside |
| title_fullStr | Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside |
| title_full_unstemmed | Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside |
| title_short | Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside |
| title_sort | mucosal injury during anti cancer treatment from pathobiology to bedside |
| topic | mucosal injury mucositis mucosal impairment anti-cancer treatments |
| url | https://www.mdpi.com/2072-6694/11/6/857 |
| work_keys_str_mv | AT deborabasile mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT paoladinardo mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT carlacorvaja mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT silviokengarattini mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT giacomopelizzari mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT camillalisanti mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT luciabortot mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT luciadaros mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT michelebartoletti mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT matteoborghi mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT lorenzogerratana mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT davidelombardi mucosalinjuryduringanticancertreatmentfrompathobiologytobedside AT fabiopuglisi mucosalinjuryduringanticancertreatmentfrompathobiologytobedside |